Shares of Knight Therapeutics Inc. (TSE:GUD – Get Free Report) were up 2% on Monday . The stock traded as high as C$9.70 and last traded at C$9.66. 55,797 shares traded hands during mid-day trading, a decline of 42% from the average daily volume of 96,049 shares. The stock had previously closed at C$9.47.
Analysts Set New Price Targets
Separately, Canaccord Genuity Group set a C$9.50 price target on Knight Therapeutics and gave the company a “buy” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of C$9.50.
Knight Therapeutics Stock Down 0.2%
Knight Therapeutics (TSE:GUD – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported C($0.03) earnings per share (EPS) for the quarter. The business had revenue of C$143.97 million during the quarter. Knight Therapeutics had a net margin of 2.72% and a return on equity of 1.91%. Sell-side analysts anticipate that Knight Therapeutics Inc. will post 0.1009486 EPS for the current fiscal year.
Knight Therapeutics Company Profile
Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.
Recommended Stories
- Five stocks we like better than Knight Therapeutics
- Ulta Beauty’s Earnings Beat Was Stronger Than the Stock’s Reaction
- Bancorp’s Fintech Comeback Gains Momentum
- What Does Apple’s TV Price Hike Say About Where the Stock Is Heading?
- Will the Most Successful Quantum Firms Be Software Companies?
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
